StreetInsider.com News Articles

Kenneth T. Mills resigns from Regenxbio board

Fri, 16 Oct 2026 07:05:05 -0400

Kenneth T. Mills resigned from the board of directors of Regenxbio (NASDAQ: RGNX), effective October 21, 2026, according to a company statement. Mills submitted his resignation on October 14, 2026, after becoming chief executive officer of another company.

The company stated that Mills' departure was not related to any disagreement with Regenxbio over its operations, policies, or practices.

Following Mills' exit, the board appointed George Migausky as Chairman of the Board. As Migausky is an independent director, Daniel Tassé stepped down from his role as Lead Independent Director in accordance with the company's Corporate Governance Guidelines, but will remain a board member.

Kenneth T. Mills resigns from Regenxbio board

Fri, 16 Oct 2026 07:05:05 -0400

The company stated that Mills' departure was not related to any disagreement with Regenxbio over its operations, policies, or practices.

Form 8-K REGENXBIO Inc. For: Oct 14

Fri, 16 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27195554.html

Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO

Tue, 13 Oct 2026 13:38:00 -0400

si-local-file:///var/storage/secattach/20261013/27180399.html

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Mon, 12 Oct 2026 07:05:00 -0400

Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026

ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

Mon, 12 Oct 2026 07:05:00 -0400

Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026

ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/

Mizuho Starts Regenxbio Inc. (RGNX) at Outperform

Mon, 05 Oct 2026 04:22:05 -0400

Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Outperform rating and a price target of $22.00.

The analyst comments: “We initiate on RGNX at OP/$22 PT (implies 196% upside). RGNX is developing gene therapy-based candidates for diseases of high unmet need, and we model two lead assets: (1) RGX-202 for Duchenne muscular dystrophy/DMD (for which pivotal P3 data are already in hand — thereby de-risking the asset — and a US regulatory filing is expected in 1Q27); and (2) ABBV-RGX-314 (aka sura-vec) for wet AMD/wAMD and diabetic retinopathy/DR (partnered with AbbVie (ABBV, NC), and for which

Mizuho Starts Regenxbio Inc. (RGNX) at Outperform

Mon, 05 Oct 2026 04:22:05 -0400

Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Outperform rating and a price target of $22.00.

H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Mon, 28 Sep 2026 06:59:40 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $21.00 price target on Regenxbio Inc. (NASDAQ: RGNX).

The analyst commented: "Three-year results demonstrate durable efficacy in diabetic retinopathy. Last week, REGENXBIO presented long-term follow-up data from the Phase 2 ALTITUDE study of surabgene lomparvovec (sura-vec; ABBV-RGX-314) in non-proliferative diabetic retinopathy (NPDR). At Dose Level 3 (1.0×10¹² GC/eye, suprachoroidal delivery), 60% of participants with three-year visits (6/10) achieved a ≥2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) without additional treatment for diabetic retinopathy. These participants did not experience any vision-threatening events. Additionally, three of four participants who achieved a one-step

Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Fri, 25 Sep 2026 09:14:21 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $42.00 price target on Regenxbio Inc. (NASDAQ: RGNX).

The analyst commented, "We reiterate our Buy rating on RGNX, $42 TP. Further supporting suprachoroidal/SC administration of Sura-vec (ABBV-RGX-314) in diabetic retinopathy/DR, new 3-year data were reported from DL3 in the Ph.2 ALTITUDE study, demonstrating not only durability but an expanding number of patients (60%) reaching a ≥2-step improvement in DRSS without any additional DR treatment nor vision threatening events/VTE. Even in patients with VTE, ALL either improved or remained steady from Year 1 to Year 3. Notably, this was with NO new safety

Regenxbio stock gains on positive gene therapy trial data

Fri, 25 Sep 2026 09:09:32 -0400

Investing.com -- Regenxbio Inc (NASDAQ:RGNX) shares rose 4.8% in premarket trading Friday after the company presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting.

The Phase II ALTITUDE study showed that 60% of Dose Level 3 participants with three-year visits achieved greater than 2-step improvement on the Diabetic Retinopathy Severity Scale without additional treatment for diabetic retinopathy. These participants did not experience any vision-threatening events.

The data showed that the

Regenxbio stock gains on positive gene therapy trial data

Fri, 25 Sep 2026 09:09:32 -0400

The data showed that the

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Thu, 24 Sep 2026 19:17:00 -0400

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Thu, 24 Sep 2026 19:17:00 -0400

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy

Regenxbio settles patent dispute with Sarepta for $39M

Wed, 23 Sep 2026 16:09:19 -0400

Regenxbio Inc. (NASDAQ: RGNX) and The Trustees of the University of Pennsylvania reached a settlement agreement with Sarepta Therapeutics Inc. (together with Sarepta Therapeutics Three, LLC) and Catalent Inc. to resolve patent infringement litigation related to Sarepta's Duchenne muscular dystrophy gene therapy ELEVIDYS.

Under the terms of the agreement, dated September 23, 2026, Sarepta will pay $39.0 million to Regenxbio within 10 days of the agreement's effective date. Following the payment, all ongoing patent litigation concerning U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274 will be terminated with prejudice.

As part of the settlement, Regenxbio and UPenn agreed to release all

Regenxbio settles patent dispute with Sarepta for $39M

Wed, 23 Sep 2026 16:09:19 -0400

As part of the settlement, Regenxbio and UPenn agreed to release all

Form 8-K REGENXBIO Inc. For: Sep 23

Wed, 23 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260923/27096763.html

Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260827/26991651.html

Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260827/26991651.html

Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991648.html

Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991648.html

Regenxbio Inc. (RGNX) PT Lowered to $21 at H.C. Wainwright

Wed, 26 Aug 2026 06:44:49 -0400

(Updated - August 26, 2026 6:44 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $21.00 (from $23.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, REGENXBIO announced that the FDA had placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. The findings were identified through an expanded MRI monitoring plan, implemented by the company a few months ago following the clinical hold related to RGX-111. The five participants received intracisternal or intraventricular RGX-121 approximately three to six years ago. Investigators